CO2017007693A2 - Formulación acuosa estable de anticuerpo anti-factor de crecimiento celular endotelial vascular (vegf) - Google Patents

Formulación acuosa estable de anticuerpo anti-factor de crecimiento celular endotelial vascular (vegf)

Info

Publication number
CO2017007693A2
CO2017007693A2 CONC2017/0007693A CO2017007693A CO2017007693A2 CO 2017007693 A2 CO2017007693 A2 CO 2017007693A2 CO 2017007693 A CO2017007693 A CO 2017007693A CO 2017007693 A2 CO2017007693 A2 CO 2017007693A2
Authority
CO
Colombia
Prior art keywords
antibody
vegf
growth factor
vascular endothelial
aqueous formulation
Prior art date
Application number
CONC2017/0007693A
Other languages
English (en)
Inventor
Rebecca Lee Ingram
Sarah Elizabeth Weiser
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017007693(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CO2017007693A2 publication Critical patent/CO2017007693A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al campo de las formulaciones farmacéuticas de anticuerpos. En forma específica, la presente invención se refiere a una formulación de anticuerpo líquido estable y su preparación farmacéutica y uso. Esta invención se ejemplifica por una formulación acuosa de un anticuerpo anti-factor de crecimiento vascular endotelial (VEGF).
CONC2017/0007693A 2015-01-28 2017-07-28 Formulación acuosa estable de anticuerpo anti-factor de crecimiento celular endotelial vascular (vegf) CO2017007693A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562108811P 2015-01-28 2015-01-28
US201562265514P 2015-12-10 2015-12-10
PCT/IB2016/050273 WO2016120753A1 (en) 2015-01-28 2016-01-20 Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation

Publications (1)

Publication Number Publication Date
CO2017007693A2 true CO2017007693A2 (es) 2017-10-10

Family

ID=55315458

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0007693A CO2017007693A2 (es) 2015-01-28 2017-07-28 Formulación acuosa estable de anticuerpo anti-factor de crecimiento celular endotelial vascular (vegf)

Country Status (11)

Country Link
US (2) US10894083B2 (es)
EP (1) EP3250596A1 (es)
JP (1) JP6877878B2 (es)
CN (1) CN107206080B (es)
AU (2) AU2016210918A1 (es)
BR (1) BR112017014376A2 (es)
CA (1) CA2918714A1 (es)
CO (1) CO2017007693A2 (es)
MX (1) MX2017009759A (es)
RU (1) RU2699544C2 (es)
WO (1) WO2016120753A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
AU2019227997A1 (en) 2018-03-02 2020-09-24 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
MX2020009275A (es) * 2018-03-07 2021-01-08 Pfizer Composiciones de anticuerpo anti-pd-1.
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
AU2020316498B2 (en) 2019-07-19 2024-02-29 Sinocelltech Ltd. Humanized anti-VEGF monoclonal antibody
AU2020320222A1 (en) * 2019-08-01 2022-03-03 Gennova Biopharmaceuticals Limited Opthalmic composition of Bevacizumab
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230035617A1 (en) * 2019-11-13 2023-02-02 Pfizer Inc. Stable aqueous anti-tfpi antibody formulation
KR20220001106A (ko) * 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
CN118593699A (zh) * 2023-03-06 2024-09-06 百奥泰生物制药股份有限公司 一种稳定的抗vegf抗体制剂

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350A (en) 1849-04-17 Moetising-machine
US377A (en) 1837-09-08 Turnek whitehouse
US692A (en) 1838-04-14 Improvement in machines for mowing and cutting grass and grain
US6180A (en) 1849-03-13 Improved furnace for smelting zinc
US297A (en) 1837-07-29 Improvement in fire-arms
US867A (en) 1838-08-01 Improved adhesive compound for binding books
US6054A (en) 1849-01-23 Improved process for welding cast to wrought iron or steel
US861A (en) 1838-07-28 Improved water-wheel
US6210A (en) 1849-03-20 chambeelain
US5997A (en) 1849-01-02 Swinging bridge
US5866A (en) 1848-10-17 Dentist s deill
US671A (en) 1838-04-04 Improved machine for breaking hemp and flax
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
WO1998045331A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
NZ534542A (en) * 2002-02-14 2006-08-31 Chugai Pharmaceutical Co Ltd Antibody-containing solutions in which the formation of degradation products and insoluble particles during storage and freeze/thaw cycles is inhibited by adding a sugar and surfactant respectively
NZ582210A (en) * 2003-02-13 2011-04-29 Pfizer Prod Inc Uses of anti-insulin-like growth factor I receptor antibodies
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
HUE027096T2 (en) 2005-03-25 2016-08-29 Regeneron Pharma VEGF antagonist formulations
EP2021030A2 (en) * 2006-04-21 2009-02-11 Amgen, Inc. Buffering agents for biopharmaceutical formulations
WO2007149334A2 (en) 2006-06-16 2007-12-27 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
TWI661833B (zh) 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
LT3216803T (lt) * 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
US9155745B2 (en) 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
EP2473191B1 (en) 2009-09-04 2017-08-23 XOMA Technology Ltd. Antibody coformulations
MX2012006831A (es) * 2009-12-21 2012-08-17 Genentech Inc Formacion de anticuerpos.
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
WO2011109365A2 (en) 2010-03-01 2011-09-09 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof
EP2552411A2 (en) 2010-03-31 2013-02-06 Université de Genève Stabilized antibody preparations and uses thereof
CN104427974B (zh) 2012-05-18 2018-03-23 基因泰克公司 高浓度单克隆抗体配制剂
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
AU2013267310A1 (en) 2012-06-01 2014-12-11 Ophthotech Corporation Compositions comprising an anti-PDGF aptamer and a VEGF antagonist
CN104854133B (zh) * 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
JP6511609B2 (ja) 2013-03-13 2019-05-22 ジェネンテック， インコーポレイテッド 抗体製剤
ES2875878T3 (es) 2013-11-18 2021-11-11 Formycon Ag Composición farmacéutica de un anticuerpo anti-VEGF
CN104906576B (zh) 2014-03-13 2018-06-19 四川科伦博泰生物医药股份有限公司 可供皮下注射的高浓度抗vegf抗体配制剂
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
AU2015318001B2 (en) 2014-09-15 2021-03-25 Genentech, Inc. Antibody formulations
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
WO2016103139A1 (en) 2014-12-22 2016-06-30 Dr. Reddy's Laboratories Method for reduction of aggregates
CN106511997A (zh) 2015-09-15 2017-03-22 上海抗体药物国家工程研究中心有限公司 一种稳定的蛋白制剂
WO2017070460A1 (en) 2015-10-22 2017-04-27 Massachusetts Institute Of Technology Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation

Also Published As

Publication number Publication date
JP2016138097A (ja) 2016-08-04
RU2017123972A3 (es) 2019-03-01
RU2699544C2 (ru) 2019-09-06
CN107206080A (zh) 2017-09-26
MX2017009759A (es) 2017-10-27
US20180000933A1 (en) 2018-01-04
US20210128729A1 (en) 2021-05-06
JP6877878B2 (ja) 2021-05-26
WO2016120753A1 (en) 2016-08-04
US10894083B2 (en) 2021-01-19
BR112017014376A2 (pt) 2018-05-02
RU2017123972A (ru) 2019-03-01
AU2016210918A1 (en) 2017-07-13
AU2021245230A1 (en) 2021-11-04
EP3250596A1 (en) 2017-12-06
CN107206080B (zh) 2022-07-08
CA2918714A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
CO2017007693A2 (es) Formulación acuosa estable de anticuerpo anti-factor de crecimiento celular endotelial vascular (vegf)
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CO2018005525A2 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
MX2020003661A (es) Formas de dosificacion de liquidos, metodos de fabricacion y uso.
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
BR112017007393A2 (pt) composições de anticorpo anti-il-7r
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
EA201791717A1 (ru) Стабильные водные составы адалимумаба
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112016013562A2 (pt) Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
AR098168A1 (es) Formulación estable de insulina glulisina
EA201992027A1 (ru) Водный состав антитела против pd-l1
MX2020003495A (es) Derivados de acido boronico y sintesis de los mismos.
CO2018007810A2 (es) Formulación líquida estable de gonadotropina
MA53466A (fr) Formulation stable d'anticorps anti-osmr
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos